SIRT1 and lung adenocarcinoma: Due to silybin being a potent inhibitor of lung adenocarcinoma cell growth that interferes with SIRT1 signaling, combinatorial treatment with CAM/silybin may be used for therapeutic intervention in lung adenocarcinoma therapy in the future [38].